Literature DB >> 19596474

Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C.

Paula Bonorino1, Muhammad Ramzan, Xavier Camous, Tania Dufeu-Duchesne, Marie-Ange Thélu, Nathalie Sturm, Aurélie Dariz, Christiane Guillermet, Martine Pernollet, Jean-Pierre Zarski, Patrice N Marche, Vincent Leroy, Evelyne Jouvin-Marche.   

Abstract

BACKGROUND/AIMS: The fate of intrahepatic NK cell subsets in the course of HCV and HBV infections is not clearly understood.
METHODS: Blood and intrahepatic CD56(+) NK cell subsets (expressing NKG2A, CD158a,h or CD158b,j receptors) from HCV or HBV patients were quantified by flow cytometry and localized by immunohistochemistry in liver biopsies.
RESULTS: A significant reduction in NK cell frequency and a quantitative imbalance between CD56(bright) and CD56(dim) subsets were observed in chronic HCV patients as compared to HBV patients, underlining that the inflammatory environment is not the only cause of these phenomena. The proportions of intrahepatic NK cells expressing either NKG2A, and/or CD158a,h, CD158b,j differed significantly between HCV and HBV patients. A higher frequency of perforin among intrahepatic CD56(+)CD3(-) cells was observed in HCV compared to HBV patients. Double immunohistochemical staining showed that CD56(+)CD3(-) cells were localized within necrotic areas. Immune monitoring of circulating CD56 subsets revealed that CD3(-)CD56(bright)NKG2A(+) and CD3(-)CD56(dim)NKG2A(+) cells were positively correlated with the necroinflammatory score and inversely correlated with viral load, respectively, in HCV patients.
CONCLUSIONS: HCV and HBV affect NK cell subsets according to the status of the diseases, especially CD3(-)CD56(dim)NKG2A(+) and CD3(-)CD56(bright)NKG2A(+) cells, may be of interest for disease monitoring.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596474     DOI: 10.1016/j.jhep.2009.05.030

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  69 in total

1.  Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses.

Authors:  Nan Meng; Xiao Gao; Wei Yan; Mi Wang; Ping Liu; Xiao-Dan Lu; Shu-Juan Zhang; Ya-Qi Lu; Wang-Xian Tang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

2.  Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model.

Authors:  I-Tsu Chyuan; Hwei-Fang Tsai; Horng-Tay Tzeng; Chi-Chang Sung; Chien-Sheng Wu; Pei-Jer Chen; Ping-Ning Hsu
Journal:  Cell Mol Immunol       Date:  2015-02-09       Impact factor: 11.530

Review 3.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.

Authors:  Barbara Rehermann
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

4.  Plasmid vector-linked maturation of natural killer (NK) cells is coupled to antigen-dependent NK cell activation during DNA-based immunization in mice.

Authors:  Ren Zhu; Maryline Mancini-Bourgine; Xiao Ming Zhang; Florence Bayard; Qiang Deng; Marie-Louise Michel
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

5.  Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.

Authors:  Liang Ma; Yan-Jun Cai; Lei Yu; Jun-Yan Feng; Juan Wang; Cong Li; Jun-Qi Niu; Yan-Fang Jiang
Journal:  Antimicrob Agents Chemother       Date:  2012-12-28       Impact factor: 5.191

Review 6.  The role of innate immunity in HBV infection.

Authors:  Qiuju Han; Cai Zhang; Jian Zhang; Zhigang Tian
Journal:  Semin Immunopathol       Date:  2012-07-20       Impact factor: 9.623

7.  Activation of natural killer cells during acute infection with hepatitis C virus.

Authors:  Barbara Amadei; Simona Urbani; Angelica Cazaly; Paola Fisicaro; Alessandro Zerbini; Parvin Ahmed; Gabriele Missale; Carlo Ferrari; Salim I Khakoo
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

8.  Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines.

Authors:  Damien Sène; Franck Levasseur; Michal Abel; Marion Lambert; Xavier Camous; Céline Hernandez; Véronique Pène; Arielle R Rosenberg; Evelyne Jouvin-Marche; Patrice N Marche; Patrice Cacoub; Sophie Caillat-Zucman
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

Review 9.  Modulation of innate immunity in the tumor microenvironment.

Authors:  Elena Gonzalez-Gugel; Mansi Saxena; Nina Bhardwaj
Journal:  Cancer Immunol Immunother       Date:  2016-06-25       Impact factor: 6.968

10.  Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection.

Authors:  Xiaoli Hu; Yanfang Jiang; Xiurong Li; Yanhang Gao; Xiaoli Guo; Xiumei Chi; Hongqing Yan; Junyan Feng; Jin Zhong; Bing Sun; Xue Shao; Weihua Xiao; Yu Pan; Junqi Niu
Journal:  J Interferon Cytokine Res       Date:  2013-12-24       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.